Shlomo Yanai Joins Moelis & Company as Senior Advisor
Moelis & Company (NYSE: MC), a leading global independent investment bank, today announced Shlomo Yanai has joined the Firm as a Senior Advisor, effective immediately.
Mr. Yanai most recently served as the Chief Executive Officer and President of Teva Pharmaceutical Industries Ltd from 2007 to 2012. Prior to Teva, he served four years as the Chief Executive Officer and President of ADAMA Agricultural Solutions Ltd. During his nearly 15 years as a corporate executive, Mr. Yanai has successfully completed over 20 acquisitions and integrations.
“Shlomo’s leadership experience will be a tremendous resource for our clients,” said Ken Moelis, Chairman and CEO of Moelis & Company. “Throughout his career as an executive and board member, Shlomo has developed significant M&A experience in both structuring complex transactions and leading post-merger integration across a number of industries and geographies. His deep relationships with multinational companies in the healthcare, industrials, technology, and business services sectors will provide exceptional benefit to our clients across the globe.”
“Moelis & Company has built an exceptional reputation for putting its clients at the center of everything they do,” said Mr. Yanai. “As a corporate executive, particularly when executing M&A, I have recognized the value of independent advice and the trust that results from long-term relationships. I look forward to deepening and expanding Moelis & Company’s client relationships and adding a unique perspective to the Firm’s client dialogue.”
Mr. Yanai will continue his service as a board member at a number of companies and organizations including his role as Non-Executive Chairman of the Board of Directors and member of the Governance and Compensation Committees at Cambrex, Director of Perrigo Public Limited Company, and Chairman of the Board of Directors of Protalix BioTherapeutics.
In addition to Mr. Yanai’s current board memberships, he had previously served as a member of the Board of Directors of Lumenis, Ltd., as an Independent Director on the Board of Directors of Sagent Pharmaceuticals, Inc., and member of the Board of Directors of Bank Leumi Le-Israel.
About Moelis & Company
Moelis & Company is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors. The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors. Moelis & Company’s experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. The Firm serves its clients with about 650 employees based in 17 offices in North and South America, Europe, the Middle East, Asia and Australia. For further information, please visit: www.moelis.com.